nice entry point for nsph. although their influenza research has produced decent results they were unable to isolate the n1h1 germ in clinical studies. look for them to complete this in the near future and watch for them to move forward with prostate and vascular research. i will hold until they make progress on their own or get gobbled up by one of the big players.

nsph was recently voted one of the most innovative companies by a group from M.IT. look for nsph to increase profitability from partnerships with lly and global exposure of their diagnostic products should benefit the bottom line. nsph has the look of a sleeper that could really take off. i'm in for a dime do i have the guts to be in for a dollar? government grants from obama administration would be welcomed also.

the recent price action has been quite volatile for nsph. the average daily shares traded has increased. i suspect some short selling is to blame for the volatility. this company needs to post more news of any kind, to keep public and shareholders informed of any progress. look in april for nsph to announce increased sales and contracts with lly and possibly others. plans to sell their theragene system on a global basis would be the kind of news investors would need to invest further in this company.

nsph has risen past a major resistance price of $4.50, now priced at $5.05. because this stock reports news so infrequently, look for little growth until positive financial results are posted in april.

too much uncertainty in the market today with euro problems unresolved and also our economic numbers due out soon. as the job situation improves so does the markets. major resistance mark of dow 11000 looming. we clear that hurdle next week with good upside surprise tomorrow and nsph will benefit, if not, we track lower to dow 10700. nsph will suffer if traders choose a flight to quality.

nsph has had two very good upside trading days in a row. some good news must be pending. i see no recent news for nsph listed on it's stock page. also watch wells fargo(wfc) and blackstone group(bx) make steady gains this year as both are writing off or restructuring debt as well as profiting from a growing economy. stay the course with both wfc and bx even when the fed raises interest rates in the future (quality prevails)